Medical Imaging

Physicians utilize medical imaging to see inside the body to diagnose and treat patients. This includes computed tomography (CT), magnetic resonance imaging (MRI), X-ray, ultrasound, fluoroscopy, angiography,  and the nuclear imaging modalities of PET and SPECT. 

Thumbnail

Molecule could identify and aid treatment of aggressive breast cancers

A molecule has been found that could be leveraged to treat the most dangerous cancers of the breast, known as triple negative breast cancer, according to a Nov. 3 announcement from the City College of New York (CCNY).

Thumbnail

Grappling with the genomics of Ebola

Researchers are struggling to lock in genetic analysis related to the genetic mutability of Ebola due to delayed and incomplete data from around the world, according to a review published online today in Science.

Thumbnail

Brain DNA methylation in key genes linked to Alzheimer’s

The methylation cycles of several genetic variants—28 in fact—are associated with the hallmark neurodegeneration involved in Alzheimer’s disease (AD). Some variants were found to be associated with amyloid load and others with taupathy, according to a study published online Nov. 3 in JAMA Neurology.

FDG PET superior to SPECT for telling Alzheimer’s from DLB

Dementia imaging with FDG PET was more accurate, sensitive and specific in a comparison between Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB), according to a study published online Nov. 5 in the Journal of Nuclear Medicine.

Definiens acquired by AstraZeneca and MedImmune

Global biologics company AstraZeneca and its research and development division, MedImmune, announced yesterday that the company has acquired Definiens, a biotech firm focusing on imaging and research analysis.

Thumbnail

U.K. to gain a major brain imaging center

Cardiff University in Wales has broken ground on a $70 million brain imaging center expected to be "unique within Europe." A range of brain mapping techniques will be implemented to improve researchers' understanding of diseases like multiple schlerosis, schizophrenia and dementia.

Lantheus makes deal with Shine for Mo-99 supply

Lantheus Medical announced Monday that the international radiopharmaceutical company has entered an agreement with Wisconsin-based Shine Medical Technologies for supply of molybdenum-99 (Mo-99).

FDA increased regulation 15% over 12 years

A spike in regulatory requirements has been reported by Regulatory Focus according to data released by George Mason University's Mercatus Center for market research in Arlington, Va. According to the numbers, FDA requirements picked up 15 percent from the year 2000 until 2012.